Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical innovator developing next-generation immunotherapies through advanced protein design. This hub provides essential updates on corporate developments and research milestones for investors tracking this Nasdaq-listed company.
Access authoritative reports on key financial actions including the 2023 reverse stock split and operational restructuring designed to optimize capital allocation. Stay informed about strategic initiatives like the proposed merger and its implications for shareholder value.
Our curated news collection features verified updates on:
• Therapeutic pipeline advancements
• Corporate governance decisions
• Financial strategy implementations
• Partnership and merger developments
For direct inquiries, consult Neoleukin's official website or contact investor relations at investors@neoleukin.com. Bookmark this page for real-time updates on NLTX's progress in redefining immunotherapy treatments.
Neoleukin Therapeutics (NASDAQ:NLTX) announced the initiation of a combination arm in their Phase 1 trial assessing NL-201 alongside Merck's KEYTRUDA® for patients with relapsed or refractory solid tumors. This phase aims to evaluate safety, pharmacokinetics, and antitumor activity in up to 132 patients. The trial follows encouraging preclinical data indicating the potential for enhanced patient outcomes. NL-201, designed to activate CD8 T and NK cells, aims to improve tolerability and effectiveness, advancing Neoleukin's innovative approach to cancer treatment.
Neoleukin Therapeutics (NASDAQ: NLTX) reported financial results for Q1 2022, with cash reserves of $128.1 million, down from $142.5 million at the end of 2021. R&D expenses rose to $10.7 million, driven by clinical trial costs for NL-201, while G&A expenses decreased to $4.7 million. The net loss widened to $15.4 million, compared to $14.9 million in Q1 2021. Neoleukin is advancing its NL-201 clinical trial for solid tumors, with interim data expected in H2 2022. A separate trial for hematologic malignancies will follow based on current trial results.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will participate in two investor conferences. The first is the BofA Securities 2022 Healthcare Conference in Las Vegas on May 11, 2022, featuring a fireside chat at 1:20 p.m. Pacific. The second event is the H.C. Wainwright Global Investment Conference in Miami on May 25, 2022, where Drachman will present at 12:30 p.m. Eastern. Webcasts for both presentations will be available on the Neoleukin investor website, with archived replays accessible for 30 days.
Neoleukin Therapeutics (NASDAQ: NLTX) announced promising preclinical results for its immunotherapy candidate NL-201, demonstrating significant antitumor activity against B-cell lymphoma models. The data highlights NL-201's ability to synergize with radiation therapy, promoting robust immune responses and enhancing survival rates in murine models. A first-in-human Phase 1 trial is actively enrolling patients to assess NL-201's safety and recommended dosage. These findings indicate NL-201's potential across various cancer types and support further clinical investigations.
On April 7, 2022, Neoleukin Therapeutics (NASDAQ:NLTX) announced that its CEO, Jonathan Drachman, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 12:00 p.m. Eastern. The event will be accessible via a webcast on Neoleukin's website, with an archived replay available for 30 days post-event. Neoleukin is focusing on developing next-generation immunotherapies for cancer and autoimmune conditions through advanced protein design technology, notably its lead candidate, NL-201.
Neoleukin Therapeutics (NASDAQ:NLTX) has appointed Donna M. Cochener as its new General Counsel and Senior Vice President of Legal. Cochener brings extensive experience in public company practices and securities law from her previous role at HomeStreet, Inc., where she oversaw securities reporting and compliance. She expressed enthusiasm for joining Neoleukin, emphasizing its mission to develop new therapies for life-threatening diseases. Neoleukin focuses on designing innovative protein therapeutics for cancer and autoimmune conditions.
Neoleukin Therapeutics (NASDAQ: NLTX) announced three significant presentations at the AACR Annual Meeting from April 8-13, 2022, in New Orleans. The presentations highlight preclinical data demonstrating the efficacy of NL-201, a novel protein therapeutic, in treating hematologic cancers and its potential synergy with radiation therapy. Key findings suggest NL-201's ability to enhance antitumor immunity across various cancer indications. The sessions will showcase the compound’s antitumor activity in B cell lymphoma models and details from a first-in-human Phase 1 study.
Neoleukin Therapeutics (NASDAQ:NLTX) has reported its 2021 financial results, highlighting a cash position of $142.5 million, sufficient to fund operations into the second half of 2023. The company is advancing its clinical trial for NL-201, with interim data anticipated in the latter half of 2022. R&D expenses rose to $39.2 million in 2021, largely due to clinical activities. The net loss increased to $60.7 million, up from $33.3 million in 2020. Additionally, Rohan Palekar has joined the Board of Directors, enhancing strategic expertise.
Neoleukin Therapeutics (NASDAQ:NLTX) has announced it will report its full year 2021 financial results on March 1, 2022. The company will host a conference call at 1:30 p.m. Pacific to discuss the results and provide a corporate update. Neoleukin focuses on designing de novo protein therapeutics for cancer and autoimmune diseases. Its lead candidate, NL-201, targets improved tolerability and efficacy compared to native proteins. Archived audio of the call will be available for replay on their investor relations website.
Neoleukin Therapeutics (NASDAQ:NLTX) has announced that CEO Jonathan Drachman, M.D., will participate in a fireside chat at the Guggenheim Healthcare Oncology Talks 2022 Conference on February 10, 2022, at 1:30 p.m. Eastern. The event will be accessible via a webcast on the company's investor website, with an archived replay available for 30 days post-event. Neoleukin specializes in creating next-generation immunotherapies using advanced computational methods for protein design, focusing on innovative treatments for cancer, inflammation, and autoimmunity.
